ClinicalTrials.gg
CompletedNCT03250741DOPADUpdated Dec 17, 2018

Effects of Dopaminergic Therapy in Patients With Alzheimer's Disease

A Phase 2 interventional study of Rotigotine transdermal patch and Placebo in Alzheimer Disease, sponsored by I.R.C.C.S. Fondazione Santa Lucia. Completed at 1 site in Italy. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-12-17.

Sponsored by I.R.C.C.S. Fondazione Santa Lucia · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Jun 2016, registered Aug 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Alzheimer Disease with a site in Italy — 54 open to participants now, 73 under way, 19 of them phase 3. Alzheimer Disease · Italy.

Enrollment
131st of 170
94 · median 328
Started
2016
with 12 others
Phase 2
36 of 206
2 open now
Registered
76th of 206
by date
Lead sponsor
7 of 206
I.R.C.C.S. Fondazione Santa Lucia

Among the 206 studies in Alzheimer Disease with a site in Italy, this one is the 131st largest by enrollment of the 170 interventional ones that give a count, is one of 13 that started in 2016, is one of 36 in phase 2, and was the 76th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

54 of the 206 studies in Alzheimer Disease with a site in Italy are open now. Recruiting first, the newest first:

49 more — sign in →

All 54 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Alzheimer Disease with a site in Italy, or all of them as a file.
02

Study summary

This is phase IIa 24-week, prospective, randomized, double-blind placebo controlled study. The study is designed to evaluate the efficacy, safety, and tolerability of transdermal patch of Rotigotine (RTG) versus placebo (PLC) as add-on therapy with AChEI in patients with mild AD according to the consensus diagnostic criteria and MMSE score of ≥18 and ≤24 at screening. Two groups of patients with mild AD will be involved (50 patients each). One group will be assigned to treatment with RTG 4 mg and the other one to PLC as add on to AChEI therapy (Rivastigmine). Clinical and neurophysiological measurements will be collected before and after drug administration.

Read the detailed description

The current study has the ambition to provide first time evidence that dopaminergic stimulation may have a clinical impact in patients with mild AD.

Cognitive Assessment: Before and after the 24 weeks of treatment the ADAS-Cog, ADCS-ADL and the Frontal assessment battery (FAB) will be administered. FAB will be performed to measure changes in frontal executive functions (Apollonio et al, 2005) .

Neurophysiological investigations will be performed to identify quantifiable biomarkers underlying the effects induced by dopamine agonist on the neurodegenerative brain. The application of recent neurophysiological tools, such as the combined use of transcranial magnetic stimulation (TMS) during electroencephalography (EEG) will allow to measure how dopamine agonists are able to modulate the cortical activity of the prefrontal cortex in AD patients (Kähkönen et al., 2005; Julkunen et al., 2008), likely trough DA terminals originating from the ventral tegmental nucleus, defining the neurophysiological biomarkers of clinical improvement For EEG-TMS recordings, a TMS-compatible EEG equipment will be used for recording EEG activity from the scalp (BrainAmp 32MRplus, BrainProducts). The EEG will be continuously acquired from 64 scalp sites positioned according to the 10-20 International System. To precisely position the coil over the cortical sites across different sessions, a neuronavigation system (Softaxic, E.M.S.) will be used. Neurophysiological changes induced by dopamine-agonist will be indexed by the following measures: corticospinal excitability, cortical reactivity, connectivity and plasticity. Specifically, the cortical reactivity and cortico-cortical connectivity will be evaluated respectively over the prefrontal cortex and between connected areas. We will employ TMS-evoked cortical responses (i.e., TEPs) as a novel probe of dopamine-agonist induced cortical excitability changes (Ilmoniemi et al., 1997; Komssi and Kahkonen, 2006; Julkunen et al., 2008; Miniussi and Thut, 2009; Miniussi et al., 2012; Premoli et al., 2014). To reach this aim, TEPs will serve as markers of left prefrontal cortex (PFC) reactivity whereas the spreading of their cortical activation will serve as an index of connectivity between targeted cortex and functionally connected areas underlying frontal cognitive network.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • Rotigotine
  • Dopamine
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient (or if applicable the legally acceptable representative if different from the responsible caregiver) and the responsible caregiver have signed the Form.
  2. The patient has probable AD, diagnosed according to National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria.
  3. The patient is a man or woman, aged ≤ 85 years.
  4. The patient has a Clinical Dementia Rating (CDR) total score of 0.5 or 1 (mild) and score of 20-26 (inclusive) at Screening.
  5. Has at least one identified adult caregiver who is able to provide meaningful assessment of changes in subject behavior and function over time and provide information on safety and tolerability, and is able to verify daily compliance with study drug
  6. The patient has been treated with acetylcholinesterase inhibitor (AChEI), i.e., donepezil, galantamine, or rivastigmine, at the time of Screening

    • For at least 3 months
    • The current dosage regimen and must have remained stable for ≥ 8 weeks
    • It must be planned that the dosage regimen will remain stable throughout participation in the study

Exclusion criteria

Exclusion Criteria:

  1. Significant neurodegenerative disorder of the central nervous system other than Alzheimer's disease, e.g., Lewy body dementia, Parkinson's disease, multiple sclerosis, progressive supranuclear palsy, hydrocephalus, Huntington's disease, any condition directly or indirectly caused by Transmissible Spongiform Encephalopathy (TSE), Creutzfeldt-Jakob Disease (CJD), variant Creutzfeldt-Jakob Disease (vCJD), or new variant Creutzfeldt-Jakob Disease (nvCJD)
  2. The patients has history of seizure (with the exception of febrile seizures in childhood)
  3. , Fourth Edition - Text Revision (DSM IV-TR) criteria met for any of the following within specified period:

    • Major depressive disorder (current)
    • Schizophrenia (lifetime)
    • Other psychotic disorders, bipolar disorder, or substance (including alcohol) related disorders (within the past 5 years)
  4. Metal implants in the head (except dental), pacemaker, cochlear implants, or any other non-removable items that are to MR imaging.
  5. Evidence of disease including but not limited to pulmonary, gastrointestinal, renal, hepatic, endocrine, cardiovascular or metabolic disorder (Patients with controlled diabetes, or hypertension, or complete/partial right bundle branch block may be included in the study).
  6. Treatment currently or within 6 months before Baseline with any of the following medications:

    • Typical and atypical antipsychotics (i.e. Clozapine, Olanzapine)
    • Antiparkinson agents (e.g., levodopa, dopamine agonists, COMT inhibitors, amantadine, monoamine oxidase B inhibitors, anticholinergics etc)
    • Carbamazepine, Primidone, Pregabalin, Gabapentin
    • Memantine
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
94 participants (actual)

Study arms

  • Active comparator
    Rotigotine 4 mg

    Rotigotine transdermal patches 4 mg

    Drug: Rotigotine transdermal patch

  • Placebo comparator
    Placebo

    Placebo transdermal patches

    Other: Placebo

Interventions

  • Rotigotine transdermal patches 4mg/24hr

    Also known as: ROTIGOTINE

  • OtherPlacebo

    Placebo transdermal patches of the same size as for Rotigotine transdermal patches

    Also known as: Placebo transdermal patch

06

What researchers measure

Primary outcomes

  1. Global cognition

    Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)

    Time frame: change from baseline to Week 24

Secondary outcomes

  1. Frontal cognitive functions

    Frontal assessment battery (FAB)

    Time frame: change from baseline to Week 24

  2. Activities of daily living

    Alzheimer's disease Cooperative Study - Activities of Daily Living (ADCS-ADL)

    Time frame: change from baseline to Week 24

  3. Neurophysiological markers of cortical activity

    TEP amplitude over the PFC

    Time frame: change from baseline to Week 24

  4. Neuropsychiatric evaluation

    Neuropsychiatric Inventory (NPI)

    Time frame: change from baseline to Week 24

07

Study locations

1 site
  • Santa Lucia Foundation
    Rome, 00179, Italy
08

References and documents

Publications

  • Martorana A, Di Lorenzo F, Esposito Z, Lo Giudice T, Bernardi G, Caltagirone C, Koch G. Dopamine D(2)-agonist rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer's disease patients. Neuropharmacology. 2013 Jan;64:108-13. doi: 10.1016/j.neuropharm.2012.07.015. Epub 2012 Aug 1. PubMed 22863599 ↗
  • Martorana A, Koch G. "Is dopamine involved in Alzheimer's disease?". Front Aging Neurosci. 2014 Sep 25;6:252. doi: 10.3389/fnagi.2014.00252. eCollection 2014. PubMed 25309431 ↗
  • Koch G, Di Lorenzo F, Bonni S, Giacobbe V, Bozzali M, Caltagirone C, Martorana A. Dopaminergic modulation of cortical plasticity in Alzheimer's disease patients. Neuropsychopharmacology. 2014 Oct;39(11):2654-61. doi: 10.1038/npp.2014.119. Epub 2014 May 26. PubMed 24859851 ↗
  • Koch G, Motta C, Bonni S, Pellicciari MC, Picazio S, Casula EP, Maiella M, Di Lorenzo F, Ponzo V, Ferrari C, Scaricamazza E, Caltagirone C, Martorana A. Effect of Rotigotine vs Placebo on Cognitive Functions Among Patients With Mild to Moderate Alzheimer Disease: A Randomized Clinical Trial. JAMA Netw Open. 2020 Jul 1;3(7):e2010372. doi: 10.1001/jamanetworkopen.2020.10372. Erratum In: JAMA Netw Open. 2020 Aug 3;3(8):e2019190. doi: 10.1001/jamanetworkopen.2020.19190. PubMed 32667654 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Nov 2018, 29 months.

Of 127 non-industry phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 69. This study's 29 months is below that.

Counting every sponsor, half of 258 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2017
First posted
Aug 16, 2017
StartActual
Jun 2016
Primary completionActual
Nov 2018
CompletionActual
Nov 2018
Last update
Dec 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03250741
Lead sponsor
I.R.C.C.S. Fondazione Santa Lucia
Responsible party
Giacomo Koch (PI, I.R.C.C.S. Fondazione Santa Lucia) — Principal investigator
First posted
Aug 16, 2017
Start date
Jun 2016
Primary completion
Nov 2018
Completion
Nov 2018
Last update
Dec 17, 2018

Study contacts

Alessandro Martorana, MD, PhD
study director · University of Rome Tor Vergata
Giacomo Koch, MD, PhD
principal investigator · Santa Lucia Foundation IRCCS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion